Table 3.
N-acetylcysteine utilization pattern and patient outcome.
| Variable | n (%) |
|---|---|
|
| |
| Type of NAC regimen | |
| Oral | 150 (98.7) |
| Intravenous | 2 (1.3) |
| Prescriber speciality | |
| Internal Medicine | 42 (27.6) |
| Surgical | 34 (22.4) |
| Cardiology | 28 (18.4) |
| Urology | 20 (13.2) |
| Nephrology | 9 (5.9) |
| Orthopedic | 7 (4.6) |
| Others | 12 (7.9) |
| Type of procedure | |
| Computed tomography | 112 (73.7) |
| Coronary angiogram/angioplasty | 25 (16.4) |
| Digital subtraction angioplasty | 6 (3.9) |
| Magnetic resonance imaging | 4 (2.6) |
| Renal angiogram/angioplasty | 2 (1.3) |
| Others | 3 (2.0) |
| Type of contrast | |
| High-osmolarity contrast media | 0 (0) |
| Iso-osmolarity contrast media | 0 (0) |
| Low-osmolarity contrast media | 148 (97.4) |
| Gadolinium-based | 4 (2.6) |
| Iodinated contrast volume | |
| >150 mL | 18 (11.8) |
| <150 mL | 130 (85.5) |
| Patient outcome | |
| No acute kidney injury | 100 (65.8) |
| No follow-up serum creatinine | 26 (17.1) |
| Acute kidney injury | 15 (9.9) |
| On regular dialysis | 10 (6.6) |
| Death | 1 (0.7) |